SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

Gelclair

JAGX·Jaguar Health, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already FDA-approved and commercially launched in the U.S. as of October 2024.
Why 4/10
Gelclair is already FDA-approved and commercially launched (October 2024). There is no pending hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) for this product in the next ~12 months. The next major catalyst for Jaguar Health is the Canalevia PDUFA date of December 21, 2026, which is a different drug (veterinary).
Actionable Insight NEUTRAL

Gelclair is already approved and launched, so the main thing to watch is whether Jaguar's commercial efforts gain traction in the oral mucositis market. The company has shifted strategic focus to rare-disease crofelemer programs (MVID NDA filing targeted mid-2027) and out-licensed its core Mytesi/Canalevia products to Future Pak in January 2026. Gelclair appears to be a smaller part of the portfolio now. The near-term binary catalyst for JAGX is the December 21, 2026 PDUFA for Canalevia (veterinary CID), not Gelclair.

Price Chart

Loading chart...

Executive Summary

Gelclair is an FDA-approved prescription gel for managing oral mucositis (chemo mouth), a painful side effect of cancer treatment. Jaguar Health in-licensed exclusive U.S. rights from UK-based Venture Life Group in April 2024 and launched it commercially in October 2024 through its Napo Pharmaceuticals subsidiary. It is Jaguar's third prescription product, alongside Mytesi (HIV-related diarrhea) and Canalevia (veterinary). However, Jaguar has since shifted strategic focus: in January 2026 it out-licensed Mytesi and Canalevia to Future Pak for a $16M upfront payment, and the company now describes itself as "fully a rare disease GI company" centered on crofelemer for intestinal failure. Gelclair remains a commercial product but appears to be a smaller, non-core part of the portfolio. The stock trades around $0.47 (post-reverse-split adjusted) with a roughly $7M market cap, heavy dilution from recent capital structure changes, and minimal institutional ownership.

How It Works

Gelclair is a protective gel that coats the inside of the mouth. It works by a mechanical (physical) action: it adheres to the moist surfaces of the mouth and throat, forming a protective barrier over painful sores. This helps soothe pain from oral mucositis (also called "chemo mouth"), a common side effect of chemotherapy and radiation therapy for cancer. It does not contain any active drug ingredient that gets absorbed into the body.

Trial Status

Gelclair is an FDA-approved prescription product that was already on the market before Jaguar Health in-licensed it. Jaguar launched it commercially in the U.S. in October 2024 through its Napo Pharmaceuticals subsidiary. No new clinical trials for Gelclair are being conducted by Jaguar.

The Two-Sided Case

▲ Bull Case3
Gelclair addresses a large addressable market: oral mucositis affects up to 40% of chemotherapy patients and 90% of head and neck cancer patients undergoing radiotherapy, per the National Comprehensive Cancer Network.
The product is already FDA-approved and generating prescription revenue with no further clinical development risk or regulatory binary ahead.
Jaguar in-licensed Gelclair through a 5-year exclusive U.S. agreement, providing a commercial foothold in cancer supportive care with an established product.
▼ Bear Case5
Gelclair is a small part of Jaguar's portfolio; the company has publicly shifted focus to rare-disease crofelemer programs and out-licensed its core products, suggesting Gelclair is not a strategic priority.
Jaguar Health is a micro-cap stock (~$7M market cap) with heavy dilution: recent warrant repricing to $1.00, ELOC floor price reduced to $1.10, and a reverse stock split authorized up to 1:150.
Minimal institutional interest: only 3 tracked 13F holders as of Q2 2026, with combined holdings of roughly $12,000.
The company has been consistently unprofitable with net losses; 2025 total net revenue was $11.5M, of which $11.2M came from Mytesi (which was subsequently out-licensed).
Gelclair is a mechanical-action gel with no patent-protected active ingredient, facing competition from other oral mucositis treatments and generic mouthwash protocols.

Upcoming Catalysts

  • December 21, 2026: PDUFA target action date for Canalevia (crofelemer) for chemotherapy-induced diarrhea in dogs (full FDA approval decision).
  • Mid-2027: Planned NDA filing for crofelemer for microvillus inclusion disease (MVID), an ultra-rare pediatric intestinal failure disorder.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Jaguar Health, Inc. 424B5 JAGX ·Originating report

Sources · 7

Hover a chip for the title
1 curetoday.com2 newswire.com3 newswire.com4 seekingalpha.com5 247wallst.com6 freep.com7 sec.gov